The Senior Director, Clinical Pharmacology is a key leadership role within Quantitative Clinical Pharmacology and Biosimilar Sciences (QPB), part of Global Early Clinical Development (GEC). This role provides scientific and program leadership for clinical pharmacology across Teva’s innovative pipeline, ensuring that quantitative and clinical insights are translated into robust development and regulatory strategies.
The Senior Director serves as a Clinical Pharmacology Program Lead, partnering closely with clinical, pharmacometric, and translational teams to guide first in human and early clinical development, dose selection and optimization, and regulatory readiness. This role also drives innovation initiatives that advance quantitative clinical pharmacology capabilities across QPB, GEC, and the broader R&D organization.
This role can be based out of West Chester, PA or Parsippany, NJ and will follow a hybrid schedule.
Job Responsibilities and Duties:
• Provide senior scientific and program leadership for clinical pharmacology across multiple innovative programs, from first in human through regulatory approval and beyond.
• Act as Clinical Pharmacology Program Lead, accountable for integrated clinical pharmacology strategies, study design, dose rationale, interpretation, and regulatory positioning in collaboration with Global Project Teams and Clinical Development Teams.
• Lead and oversee clinical pharmacology studies in healthy volunteers and patient populations, ensuring high quality design, execution, interpretation, and decision making.
• Integrate modeling and simulation outputs developed in collaboration with Pharmacometrics (PMX) into clinical strategy, dose justification, and regulatory narratives, applying Model Informed Drug Development (MIDD) principles.
• Partner closely with Translational & Precision Medicine (TPM) to align biomarkers, mechanistic understanding, and translational strategies with early clinical development plans.
• Lead, mentor, and develop clinical pharmacology team members, fostering a collaborative, high performing, and scientifically rigorous environment within a global matrix organization.
• Drive innovation initiatives, best practices, and cross program consistency in quantitative clinical pharmacology across R&D.